RT Book, Section
A1 Rogers, Vanessa L.
A1 Roberts, Scott W.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
SR Print(0)
ID 1166168852
T1 Antiphospholipid Syndrome in Pregnancy
T2 Current Medical Diagnosis and Treatment 2020
YR 2020
FD 2020
PB McGraw-Hill Education
PP New York, NY
SN 9781260455281
LK accessmedicine.mhmedical.com/content.aspx?aid=1166168852
RD 2022/05/23
AB The  antiphospholipid  syndrome  (APS)  is  characterized  by  the  presence  of  specific  autoantibodies  in  association  with  certain  clinical  conditions,  most  notably  arterial  and  venous  thrombosis  and  adverse  pregnancy  outcomes.  Clinically,  the  diagnosis  can  be  suspected  after  any  of  the  following  outcomes:  an  episode  of  thrombosis,  three  or  more  unexplained  consecutive  spontaneous  abortions  prior  to  10  weeks’  gestation,  one  or  more  unexplained  deaths  of  a  morphologically  normal  fetus  after  10  weeks’  gestation,  or  a  preterm  delivery  at  less  than  34  weeks  due  to  preeclampsia  or  placental  insufficiency.  In  addition  to  these  clinical  features,  laboratory  criteria  include  the  identification  of  at  least  one  of  the  following  three  antiphospholipid  antibodies:  (1)  anticardiolipin  antibodies,  (2)  anti-beta-2-glycoprotein  I  antibodies,  or  (3)  the  lupus  anticoagulant  (see  Chapter  20-09).